Senile Dementia, Alzheimer TypePhase 4NCT00208819
A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
A Phase 4 study testing risperidone, quetiapine and olanzapine in people with Senile Dementia, Alzheimer Type and Dementia, Alzheimer Type, run by Emory University at 1 site in United States.
Trial summary
The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to treat agitation in elderly patients with dementia. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease
- What is being tested?
- risperidone, quetiapine and olanzapine
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2003to Jul 2007
- Phase
- Phase 4
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- inpatients admitted to Wesley Woods Inpatient service for Dementia with psychosis and agitation; taking risperidone (up to 1.5 mg/day), quetiapine (up to 175 mg/day), or olanzapine (up to 7.5 mg/day)
Who cannot join
- prior sensitivity to risperidone, quetiapine, olanzapine or divalproex
Trial locations and contacts
1 site in 1 country.
United States1 site
Wesley Woods Geriatric Hospital
Atlanta, Georgia, 30329
About this study
Official title: Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies
The purpose of this study is to determine whether an antipsychotic medication alone or an antipsychotic medication in combination with divalproex is the most effective and safest way to treat agitation in elderly patients with dementia.
Read the detailed description
Previous researchers have attempted to establish a "target dose" for antipsychotic medications (such as risperidone, quetiapine, or olanzapine) in treating symptoms of agitation in dementia. They have tried to identify the dose with the best risk-benefit ratio for patients considering the significant side effects the medications can cause. Patients taking the doses identified respond only partially and continue to experience some symptoms of agitation, however. One study showed that in patients whose agitation symptoms were not adequately controlled by the target dose of an antipsychotic medication alone, the addition of divalproex further improved behavior in 72% of patients.
The goal of this study is to compare two standard therapies for the management of agitation symptoms in dementia patients. Subjects in this study will include patients who are admitted to the Wesley Woods Inpatient service for the treatment for dementia complicated by behavioral symptoms. After a patient reaches the target dose of risperidone (up to 1.5 mg/day), quetiapine (up to 175 mg/day), or olanzapine (up to 7.5 mg/day) and agitation symptoms are still not adequately managed, he or she will be randomized to one of two groups. Group 1 participants will continue to receive increasing doses of antipsychotic medication until symptoms are controlled or he or she is unable to tolerate the dose. Group 2 participants will continue to receive the target dose of antipsychotic medication and also receive increasing doses of divalproex until symptoms are controlled or he or she is unable to tolerate the dose. Patients will be evaluated at 4 time points during hospitalization. Patients will be evaluated using scales that measure changes in cognition, function, and behavior. Laboratory and ECG results, and scales testing for movement disorders will be done to monitor safety. The family will then be contacted about 3 months the patient's hospitalization to assess current treatment status, residential status, and health status.
- Being tested
- risperidone, quetiapine, olanzapine, divalproex
- Keywords
- Alzheimer's Disease, Geriatric, Dementia, Agitation, Behavioral Disturbances, Psychosis
- Medical subject headings
- Alzheimer Disease, Dementia, Psychomotor Agitation, Mental Disorders, Psychotic Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
risperidoneDrug
quetiapineDrug
olanzapineDrug
divalproexDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
Pittsburgh Agitation Scale (PAS)
DiMarco Rating Scale for Extrapyramidal Symptoms
UKU side effect rating scale:autonomic subscale
Behavioral Activity Rating Scale (BARS)
Visual Analog Scale for Nighttime Sleep and Daytime drowsiness (VAS)
Confusion Assessment Method (CAM)
Mini-Mental State Exam (MMSE)
Cohen-Mansfield Agitation Inventory
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2005 (estimated)
- Study startSep 2003
- Study completionJul 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Senile Dementia, Alzheimer TypeStudies of the same condition, open and under way.
- More trials run by Emory UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Emory University
- Sponsor type
- University, hospital or other
- Collaborators
- Abbott
- Responsible party
- Principal investigator, Larry Tune, MD, Emory University
- Investigators
- Larry E. Tune, MD, MAS, Principal investigator, Emory University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00208819
- Sponsor's protocol ID
- 0673-2003
- Status last verified
- Nov 2013
- First submitted
- 13 Sep 2005
- Last updated
- 13 Nov 2013
- Results posted
- No
Publications
Tune L. Management of Noncognitive Symptoms of Dementia. Essentials of Clinical Psychopharmacology, 2nd ed. 2001: 935-948.